Information Provided By: 
Fly News Breaks for December 3, 2018
GWPH
Dec 3, 2018 | 07:27 EDT
Cantor Fitzgerald analyst Elemer Piros lowered his price target for GW Pharmaceuticals to $193 citing the dilution from the recent capital raise of $345M and increased spending. The analyst, however, remains "very bullish" on GW shares and sees 57% upside potential from current trading levels. Near-term emphasis should be a focus on Epidiolex sales, says Piros, which he expects to "take off" in Q1 of 2019.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
